CCCristina Camacho-Rodríguez

Cristina Camacho-Rodríguez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cristina Camacho-Rodríguez has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lung function predicts mortality in people with serious mental illness: A 6-year follow-up study

    by Maria Jose Jaen-Moreno, David Laguna-Muñoz, Gloria Isabel del Pozo, Cristina Camacho-Rodríguez, Ipek Guler, José Angel Alcalá, Micaela Reyes-López, Montserrat Alcántara, Diego Benítez-Jurado, Cristina Ruiz-Rull, et al.

    Background: The population with a serious mental illness (SMI) shows a high risk of premature mortality. Overexposed to multiple health risks throughout life, their main threat is physical illness, which starts earlier and is not diagnosed in time. Developing preventive actions is a public health priority. Methods: This longitudinal prospective study evaluated the predictive value of lung function on all-cause mortality in patients with schizophrenia (SCHIZ) or bipolar disorder. Patients aged 40–70 years, active smokers, and without preexisting respiratory disease underwent spirometry following American Thoracic Society/European Respiratory Society 2021 standards. Mortality data were collected through December 2022. Cox proportional hazards models and Kaplan–Meier survival curves analyzed the association between lung function, specifically forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), and mortality, adjusting for relevant confounders (age, gender, abdominal circumference, and comorbidities). Results: Of 107 participants (mean age 49.3 years, 63.3% male) with SMI (72% SCHIZ) and active smokers, 8 (7.5%) died during the 6-year follow-up (5 cardiovascular and 3 cancer). Mean z -scores were −1.41 (SD = 1.22) for FEV1 and −0.99 (SD = 1.16) for FVC. Lower FEV1 and FVC z -scores were significantly associated with increased mortality risk ( p = 0.002 and p = 0.009, respectively). Kaplan–Meier analysis confirmed this association for FEV1 ( p = 0.039) and FVC ( p = 0.007) but not for gender, comorbidities (hypertension, diabetes, and dyslipidemia), or FEV1/FVC. A multivariate Cox regression model, adjusting for age and abdominal circumference, confirmed the independent predictive value of lower FEV1 z -score for mortality (hazard regression = 0.473, 95% confidence interval: 0.220–0.979, p = 0.044). Conclusions: Poorer lung function, especially lower FEV1, was independently associated with all-cause mortality in SMI. Spirometry, an easily implementable technique, could help to detect at-risk individuals and favor prevention initiatives.


  • Open Access

    Respiratory disease in people with major depressive disorder: A systematic review and Meta-analysis

    by Ana Jiménez-Peinado, David Laguna-Muñoz, María José Jaén-Moreno, Cristina Camacho-Rodríguez, Gloria Isabel del Pozo, Eduard Vieta, Javier Caballero-Villarraso, Fernando Rico-Villademoros, Fernando Sarramea

    Background: Living with major depressive disorder (MDD) reduces life expectancy, with respiratory disease being a significant threat. However, evidence on respiratory disease in this population has not yet been meta-analyzed. Methods: This meta-analysis examines respiratory disease prevalence and odds ratio (OR) in patients with MDD and treatment resistant depression (TRD). A systematic literature search was conducted, with a snowball search of reference and citation lists. Inclusion criteria covered studies in MDD and TRD patients with confirmed diagnoses of respiratory diseases (asthma, chronic obstructive pulmonary disease [COPD], pneumonia, lung cancer, and tuberculosis), comparing with a control group when possible. Results: From 4,138 retrieved articles, 15 (including 476,927 individuals with MDD, 50,680 with TRD, and 1,108,979 control group) met the inclusion criteria. In MDD patients, COPD prevalence was 9.0% (95% CI: 3.8–19.6%), asthma 8.6% (95% CI: 5.7–12.8%), and pneumonia 2.5% (95% CI: 2.2–2.9%). In TRD patients, COPD prevalence was 9.9% (95% CI: 4.2–21.9%) and asthma 10.9% (95% CI: 10.7–11.2%), but meta-analysis limited to those diseases showed no significant relative risk differences. Compared to the general population, individuals with MDD had significantly higher rates of COPD (OR 1.79, 95% CI: 1.49–2.16), even higher in younger populations (1.85 [95% CI: 1.74–1.97]) and more prevalent in women. Conclusions: This first meta-analysis on this topic shows that MDD is associated with an increased risk of respiratory illness compared to the general population. The prevalence of asthma doubles the mean described in the general population worldwide, and in COPD, women and younger people are at particular risk. Prevention policies are urgently needed.


  • Open Access

    Lung function decline in people with serious mental illness: A call to action

    by Cristina Ruiz-Rull, María José Jaén-Moreno, Gloria Isabel del Pozo, Cristina Camacho-Rodríguez, Marta Rodríguez-López, Fernando Rico-Villademoros, José Luis Otero-Ferrer, Nuria Feu, Micaela Reyes-López, Rosa M. Fiestas, et al.